TiGenix Completes EUR 12 Million Capital Increase With Strategic Investor Grifols

TiGenix Completes EUR 12 Million Capital Increase With Strategic Investor
Grifols

LEUVEN, Belgium, Nov. 22, 2013 (GLOBE NEWSWIRE) -- TiGenix NV (Brussels:TIG)
announced today the successful completion of the EUR 12 million capital
increase announced on November 20, 2013. In total, 34.188.034 new ordinary
shares were issued to Gri-Cel S.A., a fully-owned subsidiary of global
healthcare company Grifols S.A. TiGenix will prepare and, after approval by
the FSMA, publish a prospectus regarding the admittance of the new shares to
trading on NYSE Euronext Brussels, which is expected to take place in the
following weeks.

The total number of outstanding ordinary shares in TiGenix NV as of November
22, 2013 amounts to 160,476,620.

"This is a very important milestone for the company. We are delighted to have
attracted Grifols as a long-term strategic investor and potential partner,"
said Eduardo Bravo, CEO of TiGenix. "The funds allow us to continue to fully
focus on the completion of the Phase III trial with our lead product Cx601,
and to strengthen our commercial operations and the further roll-out of
ChondroCelect. Having such a reference shareholder increases our financial
stability and strengthens our position for future partnering negotiations with
third parties."

"The investment in TiGenix clearly demonstrates Grifols' commitment to enter
the field of advanced therapies and personalized medicine, as well as its
dedication to innovative therapeutic approaches. I believe there is no better
way to do so than by investing in one of the global leaders in the field of
mesenchymal stem cell therapy," said Dirk Büscher, CEO of Gri-Cel. "For
Grifols this is a strategic investment with a long-term perspective, combined
with the strong belief in the technologies that have been and are being
developed by TiGenix. There is also the hope for additional future fruitful
collaborations with TiGenix taking advantage of the magnitude of Grifols'
pipeline and products."

About TiGenix

TiGenix NV (Brussels:TIG) is a leading European cell therapy company with a
marketed product for cartilage repair, ChondroCelect®, and a strong pipeline
with clinical stage allogeneic adult stem cell programs for the treatment of
autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium)
and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
For more information please visit www.tigenix.com.

About Grifols

Grifols is a global healthcare company with a 70-year legacy of improving
people's health and well being through the development of life-saving plasma
medicines, hospital pharmacy products and diagnostic technology for clinical
use.

As a leading producer of plasma medicines, Grifols has a presence in more than
100 countries and is the world leader in plasma collection, with 150 plasma
donation centers across the U.S. Grifols is committed to increasing patient
access to its life-saving plasma medicines through significant manufacturing
expansions and the development of new therapeutic applications of plasma
proteins. The company is headquartered in Barcelona, Spain and employs more
than 11,000 people worldwide.

In 2012, Grifols' sales exceeded €2,620 billion. The company's class A shares
are listed on the Spanish Stock Exchange, where they are part of the Ibex-35
(MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo
(MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more
information visit www.grifols.com.

Forward-looking information

This document may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in
which it operates. Certain of these statements, forecasts and estimates can be
recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters that
are not historical facts. Such statements, forecasts and estimates are based
on various assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable when made but
may or may not prove to be correct. Actual events are difficult to predict and
may depend upon factors that are beyond TiGenix' control. Therefore, actual
results, the financial condition, performance or achievements of TiGenix, or
industry results, may turn out to be materially different from any future
results, performance or achievements expressed or implied by such statements,
forecasts and estimates. Given these uncertainties, no representations are
made as to the accuracy or fairness of such forward-looking statements,
forecasts and estimates. Furthermore, forward-looking statements, forecasts
and estimates only speak as of the date of the publication of this document.
TiGenix disclaims any obligation to update any such forward-looking statement,
forecast or estimates to reflect any change in TiGenix' expectations with
regard thereto, or any change in events, conditions or circumstances on which
any such statement, forecast or estimate is based, except to the extent
required by Belgian law.

CONTACT: For more information
         Eduardo Bravo
         Chief Executive Officer
         eduardo.bravo@tigenix.com
        
         Claudia D'Augusta
         Chief Financial Officer
         claudia.daugusta@tigenix.com
        
         Hans Herklots
         hans.herklots@tigenix.com
         +32 16 39 60 97